Home Cart Sign in  
Chemical Structure| 2739829-00-4 Chemical Structure| 2739829-00-4

Structure of Zidesamtinib
CAS No.: 2739829-00-4

Chemical Structure| 2739829-00-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Zidesamtinib is an inhibitor of ROS1 fusions and resistance mutations that can effectively block the action of ROS1 fusion proteins.

Synonyms: NVL-520; NUV-520

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Zidesamtinib

CAS No. :2739829-00-4
Formula : C22H22FN7O
M.W : 419.45
SMILES Code : C(C)N1C2=C(CC=3C(C=4C([C@@H](C)OC=5C=C2C=NC5N)=CC(F)=CC4)=NN(C)N3)C=N1
Synonyms :
NVL-520; NUV-520
MDL No. :N/A

Safety of Zidesamtinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Zidesamtinib

RTK

Isoform Comparison

Biological Activity

Description
Zidesamtinib (NVL-520) is an orally active, brain-penetrant inhibitor that demonstrates potent selectivity against various ROS1 fusions and resistance mutations. It exhibits IC50 values of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, while sparing TRK inhibition. Zidesamtinib serves as a valuable tool for cancer research [1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05118789 Locally Advanced Solid Tumor|M... More >>etastatic Solid Tumor Less << PHASE1|PHASE2 RECRUITING 2026-10-31 UCI Medical Center, Orange, Ca... More >>lifornia, 92868, United States|Stanford Medicine, Palo Alto, California, 94305, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|University of Colorado Cancer Center, Denver, Colorado, 80045, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|University of Miami, Coral Gables, Florida, 33146, United States|University of Chicago, Chicago, Illinois, 60637, United States|Mass General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Henry Ford Cancer Institute, Detroit, Michigan, 48202, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|NYU Langone Health, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Atrium Health Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|Ohio State University, Columbus, Ohio, 43210, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|NEXT Oncology - Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|University of Washington / Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|University Hospital Leuven, Leuven, 3000, Belgium|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|Princess Margaret Cancer Research, Toronto, Ontario, M5GG 1L7, Canada|Centre Legon Berard, Lyon, 69008, France|CHU de Nantes, Nantes, 44000, France|Claudius Regaud Institute, Toulouse, 31300, France|Institute Gustave Roussy, Villejuif, 94805, France|Cologne University Hospital, Cologne, Germany|Università Politecnica Marche, Ancona, 60121, Italy|IRCCS Istituto Tumori Giovanni Paolo II, Bari, 70124, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy|Istituto Europeo di Oncologia, Milan, 20141, Italy|Istituto Oncologico Veneto, Padova, 35128, Italy|Ospedale Santa Maria delle Croci, Ravenna, 48121, Italy|Istituto Nazionale Tumori Regina Elena, Rome, 00128, Italy|Shizuoka Cancer Center, Nagaizumi, 411-8777, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Kindai University, Osaka, 577-8502, Japan|National Cancer Center Hospital, Tokyo, 104-0045, Japan|Japanese Foundation for Cancer Research, Tokyo, 135-0063, Japan|Wakayama Medical University Hospital, Wakayama, 641-0012, Japan|Kanagawa Cancer Center, Yokohama, 241-8515, Japan|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Yonsei University Health System, Seoul, 03722, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Netherlands Cancer Institute, Amsterdam, 1066, Netherlands|University Medical Centre Groningen, Groningen, Netherlands|National University Hospital Singapore, Singapore, 119074, Singapore|National Cancer Centre Singapore, Singapore, 168583, Singapore|UOMI Cancer Center - Clinica Tres Torres, Barcelona, 08017, Spain|Vall d'Hebron University Hospital, Barcelona, 08035, Spain|University Hospital of A Coru?a, Coruna, 15006, Spain|Gregorio Mara?ón Hospital, Madrid, 28007, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|Chung Shan Medical University Hospital, Taichung, 40201, Taiwan|National Cheng Kung University Hospital, Tainan, 704017, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Royal Marsden Hospital, London, SW3 6JJ, United Kingdom Less <<
NCT06797362 Non Small Cell Lung Cancer|ROS... More >>1-positive Non-Small Cell Lung Cancer (NSCLC) Less << AVAILABLE - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.92mL

2.38mL

1.19mL

23.84mL

4.77mL

2.38mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories